Financial PositionWith approximately $1.02B in cash and runway into mid-2027, full ownership of its key assets, and catalysts across both CHD and oncology, Vir is entering a more focused and potentially more investable phase of its lifecycle.
HDV Program PotentialChronic hepatitis delta virus infection (CHD) is now Vir’s clear lead value driver in hepatitis, with the pivotal Phase 3 trial ECLIPSE 1 enrolling and ECLIPSE 2 set to initiate imminently.
Oncology Program ProspectsVir's T-cell engager (TCE) in oncology programs are progressing well, with VIR-5818 and VIR-5500 showing early efficacy and safety signals in solid tumors.